NM_152384.3:c.214G>A
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_152384.3(BBS5):c.214G>A(p.Gly72Ser) variant causes a missense change. The variant allele was found at a frequency of 0.00000436 in 1,605,950 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_152384.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BBS5 | NM_152384.3 | c.214G>A | p.Gly72Ser | missense_variant | Exon 4 of 12 | ENST00000295240.8 | NP_689597.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BBS5 | ENST00000295240.8 | c.214G>A | p.Gly72Ser | missense_variant | Exon 4 of 12 | 1 | NM_152384.3 | ENSP00000295240.3 | ||
ENSG00000251569 | ENST00000513963.1 | c.214G>A | p.Gly72Ser | missense_variant | Exon 4 of 16 | 2 | ENSP00000424363.1 |
Frequencies
GnomAD3 genomes AF: 0.00000663 AC: 1AN: 150920Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.00000412 AC: 6AN: 1455030Hom.: 0 Cov.: 29 AF XY: 0.00000414 AC XY: 3AN XY: 724236
GnomAD4 genome AF: 0.00000663 AC: 1AN: 150920Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 73594
ClinVar
Submissions by phenotype
Bardet-Biedl syndrome Pathogenic:3
Variant summary: BBS5 c.214G>A (p.Gly72Ser) results in a non-conservative amino acid change located in the first DM16 repeat (IPR014003) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6.7e-06 in 149692 control chromosomes (gnomAD v3.1, genomes dataset). The variant, c.214G>A, has been reported in the literature in multiple homozygous individuals of African origin, who were affected with Bardet-Biedl Syndrome (Hjortshoj_2008, Janssen_2011, Jespersgaard_2019, Habibi_2020). These data indicate that the variant is very likely to be associated with disease. At least one publication also reported experimental evidence, and demonstrated that the variant affected ciliogenesis and impaired hedgehog signaling in fibroblasts that were derived from homozygous patients (Brunbjerg Hey_2021). One submitter has provided clinical-significance assessment for this variant in ClinVar after 2014 without evidence for independent evaluation, and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
- -
This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 72 of the BBS5 protein (p.Gly72Ser). This variant is present in population databases (rs121908581, gnomAD 0.01%). This missense change has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 18203199). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 6161). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt BBS5 protein function with a positive predictive value of 80%. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Bardet-Biedl syndrome 5 Pathogenic:2
- -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at